BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, January 29, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2007

View Archived Issues

Preclinical data from AHA meeting on cardiac ischemia therapies

Read More

Adalimumab lowers uveitis flare rate in ankylosing spondylitis patients

Read More

Further RAPID study data show efficacy of certolizumab in rheumatoid arthritis

Read More

Neuropathic pain reduced with transdermal fentanyl

Read More

NovImmune develops novel mAbs with potential use in septic shock / News in Context

Read More

Recent patents divulge new therapeutic agents for cancer

Read More

Selective antagonists of the SST5 receptor identified at Roche

Read More

Recent Gyeongsang National University patent imparts new treatment for skin hyperpigmentation

Read More

FDA approves Bionomics' IND application for anticancer compound BNC-105

Read More

Research on gene-based reprogramming of human stem cells shows positive results for c-myc

Read More

Ardana reports positive results from clinical trial of its testosterone cream

Read More

Diamyd enters agreement with National Institutes of Health for trial of Diamyd

Read More

Chi-Med to initiate phase IIb trial of HMPL-004 for ulcerative colitis

Read More

The A3AR as putative target of autoimmune disease therapy

Read More

New treatment options for psychotic, depressive and anxiety disorders reported in recent patents

Read More

Schering-Plough reports third quarter 2007 results

Read More

Gilead announces third quarter 2007 results

Read More

Bristol-Myers Squibb and Pierre Fabre terminate license agreement for vinflunine

Read More

ALK-Abello reports positive results from GT-12 phase III clinical study of Grazax in children

Read More

Medicago reports further positive results from preclinical study of H5N1 avian influenza vaccine

Read More

FDA approves Wyeth Pharmaceuticals' Protonix for delayed-release oral suspension

Read More

GW Pharmaceuticals and Otsuka initiate phase II/III clinical trial of Sativex for cancer pain

Read More

FDA accepts for filing Schering-Plough's NDA for asenapine for schizophrenia

Read More

Medivir presents an update on clinical programs for Lipsovir and MIV-701

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 28, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 28, 2026.
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Dice spelling out D-E-A-L-?, yes, no

    Muted and missing M&As: JPM deals absent in 2026

    BioWorld
    For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing